

Federica Matteucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1175592/publications.pdf>

Version: 2024-02-01

46
papers

1,055
citations

516215

16
h-index

433756

31
g-index

48
all docs

48
docs citations

48
times ranked

1463
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. <i>Molecular Oncology</i> , 2022, 16, 538-548.	2.1	4
2	3-T magnetic resonance-guided high-intensity focused ultrasound (3T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	9
3	Radiomics Analysis on [68Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial. <i>Cancers</i> , 2022, 14, 1888.	1.7	12
4	177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 152-160.	3.3	20
5	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	1.4	19
6	Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098563.	1.4	19
7	Exploratory Analysis of 18F-3 TM -deoxy-3 TM -fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 601053.	1.3	11
8	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	2.9	13
9	Targeted radioactive therapy for prostate cancer. <i>Lancet, The</i> , 2021, 398, 487-488.	6.3	0
10	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021, 141, 109821.	1.2	19
11	[[18F]Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review. <i>Current Medical Imaging</i> , 2021, 17, .	0.4	2
12	Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 721821.	1.3	14
13	Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 740676.	1.3	17
14	SUV95th as a Reliable Alternative to SUVmax for Determining Renal Uptake in [68Ga] PSMA PET/CT. <i>Molecular Imaging and Biology</i> , 2020, 22, 1070-1077.	1.3	4
15	Is It Time to Introduce PET/CT in Rectal Cancer Guidelines?. <i>Clinical Nuclear Medicine</i> , 2020, 45, 611-617.	0.7	7
16	68Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. <i>Biomedicines</i> , 2020, 8, 536.	1.4	11
17	Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen). <i>Frontiers in Oncology</i> , 2020, 10, 531660.	1.3	15
18	Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3008-3017.	3.3	37

#	ARTICLE	IF	CITATIONS
19	Is It Time to Introduce PET/CT in Colon Cancer Guidelines?. <i>Clinical Nuclear Medicine</i> , 2020, 45, 525-530.	0.7	14
20	A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. <i>Journal of Visualized Experiments</i> , 2020, .	0.2	8
21	PET/CT in Multiple Myeloma: Beyond FDG. <i>Frontiers in Oncology</i> , 2020, 10, 622501.	1.3	24
22	Importance of PET with ⁶⁸ Ga-Labeled Somatostatin Analogs (perspective on) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 632 Td Medicine</i> , 2020, 61, 187S-198S.	2.8	0
23	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	8
24	Ten-year experience of the multidisciplinary Osteoncology Center. <i>Supportive Care in Cancer</i> , 2019, 27, 3395-3402.	1.0	16
25	Intego™ infusion system: cost effectiveness analysis focusing on dosimetry, sterility and management. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 183-190.	0.4	0
26	Investigation of receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 923-930.	3.3	56
27	Prognostic value of ¹⁸ F- ¹⁸ choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 348-354.	3.3	22
28	⁶⁸ Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2035-2044.	3.3	72
29	Prostate-specific membrane antigen and renal cell carcinoma: a new diagnostic and therapeutic target?. <i>Translational Cancer Research</i> , 2018, 7, S24-S25.	0.4	0
30	Reduction of ⁶⁸ Ga-PSMA renal uptake with mannitol infusion: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2189-2194.	3.3	30
31	Quantitative accuracy of ¹⁷⁷ Lu SPECT imaging for molecular radiotherapy. <i>PLoS ONE</i> , 2017, 12, e0182888.	1.1	21
32	Nuclear Medicine in the Clinical Management (ROLL, SNB, and PET). , 2017, , 247-264.		0
33	Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 227-238.	1.0	32
34	¹⁸ F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1276-1283.	3.3	83
35	Development of sentinel node localization and ROLL in breast cancer in Europe. <i>Clinical and Translational Imaging</i> , 2015, 3, 171-178.	1.1	2
36	¹¹¹ In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer. <i>Nuclear Medicine Communications</i> , 2015, 36, 135-142.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2015, 14, 721-727.	0.8	14
38	FDG PET/CT in autoimmune pancreatitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1264-1265.	3.3	5
39	¹⁷⁷ Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1845-1851.	3.3	103
40	Radiation dosimetry of 18F-fluorocholine PET/CT studies in prostate cancer patients. <i>Physica Medica</i> , 2014, 30, 346-351.	0.4	8
41	Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>Oncotarget</i> , 2014, 5, 12448-12458.	0.8	92
42	Role of 18FDG PET/CT in patients treated with ¹⁷⁷ Lu-DOTATATE for advanced differentiated neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 881-888.	3.3	123
43	FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy. <i>Journal of Cancer</i> , 2012, 3, 241-245.	1.2	33
44	Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). <i>American Journal of Hematology</i> , 2011, 86, 79-80.	2.0	5
45	Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis. <i>Nuclear Medicine Communications</i> , 2006, 27, 213-222.	0.5	16
46	Incremental diagnostic value of dobutamine stress echocardiography and dobutamine scintigraphy (technetium 99m-labeled sestamibi single-photon emission computed tomography) for assessment of presence and extent of coronary artery disease. <i>Journal of Nuclear Cardiology</i> , 1996, 3, 212-220.	1.4	24